Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 116

Weizmann Institute duo nab $12m

The funding will be funnelled into an unnamed p53 suppressor-focused oncology Weizmann spinout and ultrasound guidance device maker On-Sight Medical.

Mar 22, 2019

Sapien Cyber locks down funding

Oil and gas exploration company Woodside Energy was sufficiently intrigued in its earlier development pact with ECU-founded Sapien Cyber to purchase a 10% stake.

Mar 20, 2019

Qart Medical instills funding

TAU-founded Qart Medical has been backed by the university’s Technology Innovation Momentum Fund and Chartered Investment Managers, itself a partner in TAU Ventures.

Mar 19, 2019

Corporate venturing deal net: 11-15 March 2019

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Mar 15, 2019

Gencove adds $3m to funding sequence

New York Genome Center-founded Gencove has added $3m from investors including Alexandria Venture Investments to bring its genomics testing kit to new markets.

Mar 15, 2019

Phasecraft executes funding

Based on UCL and Bristol research, Phasecraft is a member of a UK government-backed quantum collaboration driven by both universities together with the Google Quantum AI Lab.

Mar 15, 2019

Sharpen phones IU in $15m round

IU Philanthropic Venture Fund was among the investors in the contact centre platform creator's round, which will help grow the business through recruitment and product development.

Mar 15, 2019

Well Doc recuperates with $1.6m

Scotiabank has supplied University of Calgary-affiliated Well Doc Alberta with funding under a pact signed when it bought MD Financial Management last year.

Mar 14, 2019

Parkwalk shifts return in Animal Dynamics

Parkwalk Advisors has sold on most of its stake in Oxford-founded drone designer Animal Dynamics, securing a 6.9 times return.

Mar 14, 2019

CIC turns up for Gyroscope

Gyroscope Therapeutics recently commenced phase 1/2 clinical trials on a retinal gene therapy for dry age-related macular degeneration.

Mar 11, 2019
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here